SCHEMBL6929338

SCHEMBL6929338

OCc1cncn1Cc1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 6/20 0.51
CYP11B2 P19099 6/20 0.51
GPBAR1 Q8TDU6 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
MAP3K14 Q99558 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GPR35 Q9HC97 1/20 0.43
ACP1 P24666 1/20 0.43
FNTA P49354 3/20 0.41
FNTB P49356 3/20 0.41
PGGT1B P53609 2/20 0.41
CYP19A1 P11511 2/20 0.41
P2RX7 Q99572 1/20 0.40
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10795646 0.86 SMN1; SMN2 (0.44) CYP11B1CYP11B2GPBAR1SMN1; SMN2LMNA
SCHEMBL6927023 0.85 KCNH2 (0.44) CYP11B1CYP11B2FNTAFNTBPGGT1B
Hydrochloric Acid SCHEMBL6926762 0.84 SMN1; SMN2 (0.47) CYP11B1CYP11B2GPBAR1SMN1; SMN2LMNA
SCHEMBL2441843 0.83 CYP11B2 (0.52) CYP11B1CYP11B2MEN1POLBKMT2A
SCHEMBL6928773 0.81 CYP11B1 (0.48) CYP11B1CYP11B2LMNAMEN1POLB
SCHEMBL3079356 0.80 CYP11B1 (0.71) CYP11B1CYP11B2POLBP2RX7
Hydrochloric Acid SCHEMBL7657123 0.80 CYP11B1 (0.47) CYP11B1CYP11B2LMNAMEN1POLB
SCHEMBL6923450 0.79 CYP2C19 (0.53) CYP11B1CYP11B2LMNAPOLBRAB9A
SCHEMBL12820668 0.78 CYP11B1 (0.58) CYP11B1CYP11B2SMN1; SMN2LMNAMEN1
SCHEMBL10792243 0.77 P2RX7 (0.43) CYP11B1CYP11B2GPBAR1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1045846-B1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD (KR) 2003-05-02 EP disclosed
US-6518429-B2 Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus LG CHEMICAL, LTD. (KR) 2003-02-11 US disclosed
US-6472526-B1 SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES LG CHEMICAL LTD. (KR) 2002-10-29 US disclosed
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof LG CHEMICAL LTD. 2002-09-26 US disclosed
US-6268363-B1 ANTITUMOR LG CHEMICAL LTD. (KR) 2001-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof FNTA, FNTB, FDPS CYP11B1 74/4885CYP11B2 110/4885GPBAR1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.